603229 奥翔药业
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)4.1705.7509.37114.09517.333
总资产报酬率 ROA (%)3.0974.3046.9709.64111.330
投入资产回报率 ROIC (%)3.3514.7487.87411.43313.573

边际利润分析
销售毛利率 (%)62.38953.50954.23355.04851.501
营业利润率 (%)34.78317.66630.32235.60733.708
息税前利润/营业总收入 (%)41.51218.04027.23831.47927.939
净利润/营业总收入 (%)31.31516.47026.00231.08630.786

收益指标分析
经营活动净收益/利润总额(%)106.90588.63891.51096.38298.049
价值变动净收益/利润总额(%)0.79715.80211.8090.2412.473
营业外收支净额/利润总额(%)-0.033-1.553-0.393-0.021-0.725

偿债能力分析
流动比率 (X)2.6422.4662.5342.1721.525
速动比率 (X)2.1251.9251.9391.6991.095
资产负债率 (%)25.01426.44523.82327.44336.893
带息债务/全部投入资本 (%)18.82618.00614.16714.95120.263
股东权益/带息债务 (%)424.963448.320596.424558.661384.038
股东权益/负债合计 (%)299.776278.144319.760264.394171.056
利息保障倍数 (X)6.15928.001-9.187-7.639-5.056

营运能力分析
应收账款周转天数 (天)66.88375.89373.55158.96647.334
存货周转天数 (天)296.963390.341378.875336.194273.793